Under the Paperwork Reduction Act of 1995, no persons are require

PTO/SB/O8A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

2 Sheet of

red to respond to a collection	of information unless it contains a valid OMB control number
	Complet if Kn wn
Application Number	09/640,852
Filing Date	August 17, 2000
First Named Inventor	NEHME, et al.
Art Unit	1647
Examiner Name	Gary Kunz Robert LANDSMAN
Attorney Docket Number	600-41-PA

1		PATENT DOCUMENTS	U.S.			
]	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Name of Patentee or Applicant of Cited Document	Publication Date MM-DD-YYYY	Document Number Number-Kind Code ² (if known)	Cite No.1	Examiner Initials*
		Pershadsingh et al.	02/22/2000	US-6,028,088		BL
		Weber et al.	09/05/2000	US-6,114,348		pl
				US-		***************************************
				US-		
				US-		
				US-		
				US-		
				US-		
出し	RECEIVE			US-		
				US-		
242				US-		
JUS	JAN 2 3 20			US-		
				US-		
a a n/291	TECH CENTER 16			US-		
	IEOU OFINITIO			US-		
				US-		
				US-		
				US-		
				US-		
				US-		

FOREIGN PATENT DOCUMENTS						
Examiner Initjals*	Cite No.¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
BC		PCT-US98-03355	27.08.98	Vision Pharmaceuticals		
M		PCT-US01-10410	11.10.2001	Allergan Sales, Inc.		
RL		PCT-IE02-00001	11.07.2002	Shanahan-Prendergast		
p		PCT-EP01-10172	14.03.2002	Pharmacia & UpJohn		
		= 4				

Examiner Signature	Laudel	Date Considered	3/20/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

There office that issued the document, by the two-letter code (WIPO Standard ST 3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. any comments on the amount of time you are required complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES FOR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Compl te if Kn wn **Applicant Number** 09/640,852 SUPPLEMENTAL Filing Date August 17, 2000 INFORMATION DISCLOSURE **First Named Inventor** NEHME, et al. STATEMENT BY APPLICANT Group Art Unit 1647 Gary Kunz Robert LAMPOMAN **Examiner Name** (use as many sheets as necessary) Attorney Docket Number of Sheet 600-41-PA

		OTHER RRIOR ART. MON RATENT LIERATURE ROOMMENTS	
	·	OTHER PRIOR ART – NON PATENT LIERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pate(s), volume-issue number(s), publisher, city and/or country where published	T²
RL		DiSepio et al., Retinoic Acid Receptor-Nuclear Factor-Interleukin 6 Antagonism, XP-001127433, The Journal of Biological Chemistry, Vol. No. 41, Issue of October 10, pp 25555-25559 (1997)	
W		Shi-Yong Sun and Reuben Lotan, Retinoids as chemopreventive and therapeutic agents, XP008010833, Drugs of the Future 1998, 23(6): 621-634 (1998)	
		RECEIVED	
		JAN 2 3 2003	
		TECH CENTER 1600/2	
	<u> </u>		
L			<u> </u>
Examir Signatu		Date Considered 3/20/03	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.